Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a phase 3 trial at 48 weeks - Buti, M; Wedemeyer, H; Aleman, S (Dig Liver Dis, 2023)